Alpha-lipoic acid (ALA, also called thioctic acid) is a sulfur-containing fatty acid synthesized endogenously from octanoic acid in mitochondria, where it serves as an essential cofactor for two critical enzyme complexes: pyruvate dehydrogenase (PDH, which converts pyruvate to acetyl-CoA) and α-ketoglutarate dehydrogenase (α-KGDH, a Krebs cycle enzyme). In both complexes, the dithiolane ring of ALA undergoes reversible reduction to DHLA (dihydrolipoic acid, the reduced form) during the catalytic cycle. This redox cycling between ALA and DHLA is the chemical basis of its antioxidant and electron-transfer function.
The property that distinguishes ALA from virtually every other antioxidant is its amphiphilicity: it is both water-soluble (the oxidized ALA form) and fat-soluble (both forms). Vitamin C is exclusively water-soluble; vitamin E is exclusively fat-soluble. This means each protects only the compartment it can access. ALA and DHLA operate in both the cytoplasm (aqueous) and cell membranes and lipoproteins (lipid phase), which is why it is called the "universal" or "network" antioxidant. It also directly regenerates oxidized forms of the other network antioxidants: ALA/DHLA reduces oxidized vitamin C (dehydroascorbate → ascorbate), regenerates vitamin E (tocopheroxyl radical → α-tocopherol), regenerates glutathione (GSSG → GSH via NADH-dependent mechanisms and cysteine supply), and directly reduces CoQ10.
ALADIN Trials + SYDNEY 2
the diabetic neuropathy evidence — the most replicated ALA clinical endpoint: ALADIN I (Ziegler D et al., 1995, Diabetologia): the foundational ALA RCT; DESIGN: multicenter, double-blind, placebo-controlled; N=328 patients with T2DM + symptomatic peripheral diabetic neuropathy; INTERVENTION: intravenous ALA 1,200mg, 600mg, or 100mg/day × 3 weeks vs placebo; PRIMARY OUTCOME: Total Symptom Score (TSS) — a validated scale measuring neuropathic symptoms (burning, pain, tingling, numbness); RESULT: ALA 600mg IV: −39% reduction in TSS from baseline vs −15% for placebo (p < 0.001); ALA 1,200mg IV: similar efficacy to 600mg but more adverse effects; ALA 100mg: no significant benefit; 600mg IV emerged as the optimal dose; ALADIN II (Ziegler 1999, Free Radical Biology and Medicine): 2-year RCT, oral ALA 600mg or 1,200mg BID × 2 years in patients with early peripheral neuropathy; electrophysiological stabilization (NCV preservation) vs placebo; ALADIN III (Ziegler 1999, Diabetes Care): IV loading (600mg × 3 weeks) followed by oral maintenance; confirmed IV-to-oral transition; SYDNEY 2 (Ziegler 2006, Diabetes Care): the pivotal oral ALA RCT; N=181 T2DM patients with symptomatic DPN; DESIGN: 5-week parallel-group trial of oral ALA 600mg, 1,200mg, or 1,800mg once daily vs placebo; PRIMARY OUTCOME: TSS change from baseline; RESULT: ALA 600mg: −51% TSS reduction vs −32% placebo (p=0.003); ALA 1,200mg: similar; ALA 1,800mg: greater GI adverse effects without additional efficacy; NATHAN 1 TRIAL (Ziegler 2011, Diabetes Care, N=460): 4-year oral ALA 600mg/day in early DPN; primary endpoint (NIS+7 composite score) did not reach significance at 4 years; secondary analysis: significant benefit in a subgroup; INTERPRETATION: IV ALA has the strongest evidence (ALADIN I); oral ALA has consistent evidence for symptom reduction in the medium term; the 4-year NATHAN trial's neutral primary endpoint suggests effects on electrophysiological progression may require IV delivery or higher doses for disease modification; European guideline position (German Diabetes Society, EAN guidelines): IV ALA 600mg for 3 weeks is first-line for symptomatic DPN; oral ALA 600mg/day as maintenance or for milder DPN
R vs S Form — Bioavailability
the most important supplement formulation decision: ALA STEREOCHEMISTRY: alpha-lipoic acid has one chiral center (asymmetric carbon) → two enantiomers; R-ALA (R-alpha-lipoic acid): the natural form; synthesized in the body and found in food; the form that serves as an enzyme cofactor (PDH and α-KGDH require only R-ALA); has full biological activity; S-ALA: the synthetic mirror image; NOT found in nature in significant quantities; NOT functional as an enzyme cofactor; RACEMIC vs PURE R-ALA: most commercial "alpha-lipoic acid" supplements contain racemic (50:50) R/S mixtures produced by chemical synthesis; cost: racemic is approximately 3–5× cheaper to manufacture than pure R-ALA; BIOAVAILABILITY DIFFERENCES: Carlson DA et al. (2007, Regulatory Toxicology and Pharmacology): head-to-head pharmacokinetics study comparing oral R-ALA vs racemic ALA; result: at equivalent doses, R-ALA produced 3–5× higher peak plasma concentrations than the R portion of the racemic mixture; the S-enantiomer in the racemic mix competes for absorption and first-pass metabolism → the R portion is less bioavailable in the presence of S than when given alone; CLINICAL DOSE EQUIVALENCE: 300mg R-ALA ≈ 600mg racemic ALA in terms of biologically active R-enantiomer delivery; this means: if using R-ALA, 300mg/day may be sufficient; if using standard racemic ALA, 600mg/day is needed to achieve equivalent active dose; WHY S-ALA MAY NOT BE INERT: S-ALA does not serve as an enzyme cofactor, but it IS biologically active — it can compete with R-ALA for binding at the mitochondrial PDH complex without functional activity (partial agonist/antagonist behavior); at high doses, the S-enantiomer may accumulate in mitochondria and inhibit R-ALA function; this theoretical concern is not established in human clinical data at normal supplement doses; PRACTICAL RECOMMENDATION: R-ALA is the superior form for supplementation; the premium cost (>2× racemic) is justified if taking ALA for neuropathy (where dose precision matters) or for metabolic/longevity purposes; racemic ALA is acceptable for general antioxidant purposes at 600mg/day; R-ALA stabilization: R-ALA is less stable than racemic ALA and tends to polymerize at high temperatures; look for R-ALA in sodium or potassium salt form (Na-R-ALA, K-RALA) which are more stable; or "stabilized R-ALA" in the product description
Antioxidant Network Effects
regenerating the body's entire antioxidant system: THE ANTIOXIDANT NETWORK CONCEPT (Packer L, 1995): Lester Packer at UC Berkeley formalized the concept that antioxidants don't work in isolation — they form a regeneration network where reduced forms of one antioxidant recycle oxidized forms of another; ALA/DHLA is the central hub of this network: REGENERATES VITAMIN C: dehydroascorbate (oxidized vitamin C) + DHLA → ascorbate (reduced vitamin C) + ALA; this keeps vitamin C in its active ascorbate form, extending its effective half-life; REGENERATES VITAMIN E: tocopheroxyl radical (oxidized vitamin E, after donating H• to quench a peroxyl radical) + DHLA → α-tocopherol (reduced vitamin E) + ALA; vitamin E is otherwise only recycled by vitamin C (slow) or CoQ10H₂ in the membrane; ALA provides an additional recycling pathway; REGENERATES GLUTATHIONE: DHLA provides two mechanisms: (1) DHLA directly reduces GSSG to 2GSH; (2) DHLA donates cysteine (via transsulfuration) → increases intracellular cysteine → feeds GSH synthesis (complementary to NAC); ALA alone has been shown to increase intracellular GSH by 30–70% in cell culture; REGENERATES CoQ10: DHLA reduces ubiquinone (oxidized CoQ10) to ubiquinol (reduced CoQ10) → CoQ10 remains in its electron-donating, antioxidant form; CHELATES HEAVY METALS: ALA and DHLA form complexes with: copper (Cu²⁺), zinc (Zn²⁺), lead (Pb²⁺), mercury (Hg²⁺), cadmium (Cd²⁺), arsenic (As³⁺); the chelation is not as strong as medical chelating agents (DMSA, DMPS) but is synergistic with antioxidant protection from metal-induced oxidative stress; in heavy metal toxicity, ALA reduces the oxidative burst triggered by redox-active metals; DIHYDROLIPOATE (DHLA) vs ALA IN RECYCLING: the DHLA form (reduced) does most of the antioxidant recycling; in vivo, ALA is reduced to DHLA primarily by dihydrolipoamide dehydrogenase (the same enzyme that reduces ALA within the PDH complex) and to a lesser extent by thioredoxin reductase and glutathione reductase; the ALA → DHLA reduction requires NADH or NADPH, linking ALA's antioxidant capacity to cellular energy status
Insulin Sensitizing + Metabolic
GLUT4 translocation and glucose metabolism: ALA AS AN INSULIN SENSITIZER: multiple RCTs and animal studies show ALA improves insulin sensitivity through a mechanism partially distinct from metformin or exercise; PRIMARY MECHANISM — GLUT4 TRANSLOCATION: in skeletal muscle, insulin signals via IRS-1 → PI3K → Akt → AS160 phosphorylation → GLUT4 vesicle translocation to the plasma membrane → glucose uptake; ALA activates PI3K directly (partially insulin-independent) → Akt phosphorylation → GLUT4 translocation → glucose uptake without insulin; ALA also activates AMPK (AMP-activated kinase) → GLUT4 translocation (the same pathway activated by exercise and metformin); SECONDARY MECHANISM — IMPROVING INSULIN RECEPTOR SENSITIVITY: ALA reduces oxidative stress → less oxidative modification of IRS-1 (Tyr phosphorylation sites that mediate insulin signaling are vulnerable to reactive oxygen species) → insulin receptor signaling is more efficient; CLINICAL INSULIN SENSITIZING EVIDENCE: Jacob S et al. (1999, Free Radical Biology and Medicine, N=74, T2DM): ALA 600mg IV × 10 days → significant improvement in insulin-stimulated glucose disposal rate (euglycemic-hyperinsulinemic clamp: +36% vs −7% for placebo; p=0.006); Konrad D et al. (2011): ALA 1,200mg/day oral × 4 weeks in T2DM: significant reduction in fasting glucose and insulin levels; HOMA-IR improvement; POLYCYSTIC OVARY SYNDROME: Genazzani AD et al. (2008, Gynecological Endocrinology): ALA 400mg TID × 6 months in PCOS: significant improvement in insulin sensitivity and menstrual cycle regularity; OBESITY AND APPETITE: ALA at higher doses (1,200–1,800mg/day) modestly reduces body weight in RCTs — proposed mechanism via hypothalamic AMPK inhibition → reduced appetite; not a primary weight loss intervention but the effect is statistically significant in meta-analyses; BIOTIN INTERACTION — IMPORTANT: at high doses (>600mg/day racemic ALA), ALA competes with biotin for uptake by the sodium-dependent multivitamin transporter (SMVT) → potential biotin deficiency with chronic high-dose ALA; supplement 2.5–5mg biotin with ALA >600mg/day if used long-term
Want the full evidence writeup?
The Stack Protocol builds four complete goal stacks — Energy, Focus, Sleep, Longevity — with exact doses, timing, budget tiers, and a 30-day rollout plan, graded with the same evidence framework behind this page.
Get the Stack Protocol → $19
| Form | Equivalent Dose | Best For | Stability | Cost |
|---|
| Racemic ALA (R/S mix) | 600mg = 300mg active R-ALA | General antioxidant; neuropathy adjunct; budget option | Good; standard shelf life | $ |
| R-ALA (pure) | 300mg = 300mg active R-ALA | Neuropathy treatment; metabolic; precise dosing | Less stable; polymerizes at heat | $$$ |
| Na-R-ALA (sodium R-ALA salt) | 330mg salt ≈ 300mg R-ALA | Best bioavailability; most stable R-ALA form | Excellent; salt prevents polymerization | $$$ |
| IV ALA (clinical) | 600mg IV = highest bioavailability | Acute symptomatic DPN (European standard of care) | N/A (clinical preparation) | Clinical prescription only |
Alpha-Lipoic Acid Protocol — Dose, Timing, Form, and Critical Interactions
Dose by indication: GENERAL ANTIOXIDANT/NETWORK SUPPORT: 300mg R-ALA or 600mg racemic ALA once daily; fasted (see timing below); start once daily, assess GI tolerance; DIABETIC PERIPHERAL NEUROPATHY (most evidence): 600mg racemic ALA or 300mg R-ALA TWICE daily (1,200mg racemic or 600mg R-ALA total); based on SYDNEY 2 data — 600mg once daily was significant; BID is consistent with European prescribing practice; allow 8–12 weeks minimum for meaningful symptom reduction; INSULIN SENSITIZING / METABOLIC: 300–600mg R-ALA (or 600–1,200mg racemic) once to twice daily; for PCOS insulin resistance: 400–600mg TID was used in trials (higher total dose than DPN protocols); add biotin 5mg/day when exceeding 600mg/day racemic ALA; TIMING — EMPTY STOMACH IS ESSENTIAL: ALA and especially R-ALA are rapidly absorbed but compete with dietary amino acids for transport; food (particularly protein) significantly reduces peak plasma concentration; take ALA 30–60 minutes before a meal or 2 hours after; the rapid absorption peak (Tmax ~30 minutes for R-ALA) means fasted timing dramatically improves both bioavailability and clinical response; BIOTIN CO-SUPPLEMENTATION: at doses ≥600mg/day (racemic) or ≥300mg twice-daily R-ALA: supplement 2.5–5mg biotin daily; biotin and ALA share SMVT (sodium-dependent multivitamin transporter); competitive inhibition at high ALA doses → potential subclinical biotin deficiency over months; symptoms of biotin deficiency: hair thinning, nail brittleness, rash — alert your physician; THYROID CAUTION: ALA at high doses (>1,200mg/day) may reduce T3 levels in animal studies; human data limited; patients on thyroid hormone replacement should monitor TSH if using high-dose ALA long-term; BLOOD SUGAR LOWERING INTERACTION: ALA's insulin-sensitizing effects can add to the hypoglycemic effect of insulin, sulfonylureas, or other anti-diabetes medications → risk of hypoglycemia; T2DM patients starting ALA should monitor glucose more frequently for the first 4 weeks; possible reduction of antidiabetic medication doses may be needed; SMELL: some patients notice a sulfurous smell in urine, breath, or sweat — from ALA metabolism to sulfur-containing byproducts; harmless but alarming if unexpected; dose-dependent; reducing dose or splitting doses reduces the effect.